ONTY Share Price

Open 1.19 Change Price %
High 1.22 1 Day 0.00 0.00
Low 1.17 1 Week 0.00 0.00
Close 1.21 1 Month 0.00 0.00
Volume 715197 1 Year -1.14 -48.51
52 Week High 2.49
52 Week Low 0.90
ONTY Important Levels
Resistance 2 1.26
Resistance 1 1.24
Pivot 1.20
Support 1 1.18
Support 2 1.16
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

Oncothyreon Inc. (NASDAQ: ONTY)

ONTY Technical Analysis 2
As on 8th Jun 2016 ONTY Share Price closed @ 1.21 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.25 & Buy for SHORT-TERM with Stoploss of 1.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONTY Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ONTY Other Details
Segment EQ
Market Capital 286505600.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncothyreon.com
ONTY Address
ONTY
2601 Fourth Avenue
Suite 500
Seattle, WA 98121
United States
Phone: 206-801-2100
Fax: 206-801-2101
Interactive Technical Analysis Chart Oncothyreon Inc. ( ONTY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncothyreon Inc.
ONTY Business Profile
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company�s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, Stimuvax, is a cancer vaccine being evaluated in two Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Merck KGaA has completed enrollment of 1514 patients in the Phase III START trial of Stimuvax in NSCLC.